Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia
- PMID: 6122004
- DOI: 10.1016/s0140-6736(82)92619-8
Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia
Abstract
Seventeen patients who received allogeneic bone-marrow transplants from matched or slightly mismatched (in four patients) siblings were observed for at least 60 days or until acute graft-versus-host disease (GvHD) developed. All donor marrows after preliminary manipulation were incubated with 1 mg of the murine monoclonal antibody OKT3 before infusion in an attempt to deplete them of immunocompetent T lymphocytes (opsonisation). In three of the seventeen patients acute GvHD of grade II or greater developed. Two of these patients died, but they had disseminated cytomegalovirus infection as well as GvHD. Eleven patients showed no evidence of acute GvHD, and four had transient limited skin rashes (grade I GvHD). Opsonisation of T lymphocytes has reduced the incidence of severe acute GvHD in this unit from 79% in an earlier group of 14 patients to 18% when added to prophylactic methotrexate.
Similar articles
-
OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation.J Clin Immunol. 1982 Jul;2(3 Suppl):148S-153S. J Clin Immunol. 1982. PMID: 6290527
-
Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation.Lancet. 1982 Jun 5;1(8284):1266-9. doi: 10.1016/s0140-6736(82)92840-9. Lancet. 1982. PMID: 6123018
-
[CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].Zhonghua Er Ke Za Zhi. 2004 Apr;42(4):294-8. Zhonghua Er Ke Za Zhi. 2004. PMID: 15157394 Clinical Trial. Chinese.
-
Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.Clin Pharm. 1993 Oct;12(10):736-61. Clin Pharm. 1993. PMID: 8258255 Review.
-
T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?BioDrugs. 2003;17(3):147-54. doi: 10.2165/00063030-200317030-00001. BioDrugs. 2003. PMID: 12749751 Review.
Cited by
-
T cell regeneration after allogeneic bone marrow transplantation.Clin Exp Immunol. 1983 Oct;54(1):59-72. Clin Exp Immunol. 1983. PMID: 6352107 Free PMC article.
-
Natural killer (NK) cells and graft-versus-host disease (GVHD): no correlation between the NK cell levels and GVHD in the murine P----F1 model.Immunology. 1985 Jan;54(1):121-6. Immunology. 1985. PMID: 3972429 Free PMC article.
-
Graft-versus-host disease: a review.J R Soc Med. 1987 Jun;80(6):368-73. doi: 10.1177/014107688708000613. J R Soc Med. 1987. PMID: 3305944 Free PMC article. Review. No abstract available.
-
Graft-versus-host disease.Br Med J (Clin Res Ed). 1982 Oct 30;285(6350):1226-7. doi: 10.1136/bmj.285.6350.1226. Br Med J (Clin Res Ed). 1982. PMID: 6812816 Free PMC article. No abstract available.
-
A review of the current status and techniques of allogeneic bone marrow transplantation for treatment of leukaemia.J Clin Pathol. 1983 Nov;36(11):1207-14. doi: 10.1136/jcp.36.11.1207. J Clin Pathol. 1983. PMID: 6355192 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical